Kevin Feeley sold $1.6M of WGS
CHIEF FINANCIAL OFFICER at GeneDx Holdings Corp.. 22,000 shares at an average of $74.81, traded Nov 21, 2024, filed Nov 25, 2024.
Score components
- +22RoleCFO
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 49% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.8%, 3m +18.1%, 6m -11.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027662, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -200 | $69.58 | $14k | 44,751 | Nov 25, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -430 | $70.84 | $30k | 44,321 | Nov 25, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -969 | $71.86 | $70k | 43,352 | Nov 25, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,057 | $73.00 | $77k | 42,295 | Nov 25, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -5,524 | $73.79 | $408k | 36,771 | Nov 25, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -3,839 | $74.97 | $288k | 32,932 | Nov 25, 2024 |
| Nov 22, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -5,162 | $75.34 | $389k | 27,770 | Nov 25, 2024 |
| Nov 22, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -2,711 | $76.41 | $207k | 25,059 | Nov 25, 2024 |
| Nov 22, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -2,108 | $77.40 | $163k | 22,951 | Nov 25, 2024 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $3.0M 46,933 shares | -34% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.